Table 2.

Trials Evaluating Intravenous vs. Intracoronary Abciximab

Author Year [ref.]	N° of Patients Studied iv/ic	Population	Design	Follow-up	Evaluation	Conclusion
Belandi 2004 [53]	45 23/22	STEMI	Prospective. Randomized.	7 days. 1 month.	IS, MS, SI, left ventricular function recovery after 1 month.	↓ in IS, ↑ in MS, SI and LVEF in ic-group*.
Romagnoli 2005 [54]	74 37/37	STEMI NSTEACS	Prospective. Control-group matched by baseline-characteristics.	In-hospital.	Angiographic by CTFC. Cardiac enzymes (CK, CK-MB, TNT).	↓ in CTFC*. Trend towards ↓ of peak enzyme values in ic-group. ↓ of CK-MB peak value in STEMI-subgroup in ic-group*.
Wöhrle 2007 [55]	633	STEMI	Observational. Control: Other studies with no or iv-Abciximab	30 days.	MACE (death, myocardial infarction, urgent TVR). Bleeding.	↓ MACE in present study vs. earlier iv-studies. No safety issues.
Kakkar 2004 [56]	173 72/101	Stable angina STEMI NSTEACS	Retrospective.	6 months.	MACE (death, myocardial infarction).	MACE ↓ in ic-group, 5.8% vs. 13.9%*.
Wöhrle 2003 [57]	403 109/294	Unstable angina STEMI NSTEACS	Retrospective.	30 days.	MACE (death, myocardial infarction, urgent revascularization).	MACE ↓ in ic-group, 10.2% vs. 20.2%*.

^*P<0.05.

Abbreviations: CK: Creatin-kinase; CK-MB: Creatin-kinase-MB; CTFC: Corrected TIMI frame count; IS: Infarct Size; MACE: Major Adverse Cardiovascular events; MS: Myocardial Salvage; NSTEACS: non-ST-elevation acute coronary syndrome; SI: Salvage Index; STEMI: ST-elevation myocardial infarction; TNT: Troponin T; TVR: Target vessel revascularization.